Policy

Nordic States foster Bioeconomy
Enlarge image

BusinessFinland

Nordic States foster Bioeconomy

13.04.2012 - Finland is the last Nordic country which has not yet decided to start a nationwide bioeconomy programme. Calls for such an strategy are becoming louder.

Helsinki – Denmark has already implemented a national bioeconomy strategy, investing €1.8bn by 2015. At the end of March, Norway and Sweden announced at the "Bioeconomy in Action" conference that they would also start countrywide efforts. Norway intends to spend as much as €300m in total. Demands for Finland not to fall behind are becoming more pressing. Erkki KM Leppävuori, President and CEO of the VTT Technical Research Centre of Finland, said during a conference on April 12, "Finland should create a national bioeconomy strategy as soon as possible". According to Leppävuori, bioeconomy has all the prerequisites for creating a radical increase in the value of exports and for developing into a new pillar of support for wellbeing in Finland. "This will require the making of choices, the taking of risks, and the development and marketing of bioeconomy-based technologies", he added. Finland’s forest industry especially might profit from such a move. According to expert assessment, by 2020 new technological solutions and diversification could raise Finland's production by €6bn (equal to an increase of 22% compared to the 2010 level). Current operations could be expanded into the production of composites, biofuels and biochemicals, and into service businesses. Leppävuori already has a suggestion for facilitating the necessary changes, "The renewal of Finland’s business sector can be expedited by forming a voluntary partnership network – the Finnish Institute of Technology and Innovation (FIT). Research programs in the network could be opened up to each other and large-scale multidisciplinary projects initiated in applied research." Leppävuori added, "This is also a question of effective utilization of Finland’s limited research resources."

http://www.european-biotechnology-news.com/news/news/2012-02/nordic-states-foster-bioeconomy.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • PROTHENA PLC (IE)51.61 USD42.6%
  • PHARMING (NL)0.25 EUR31.6%
  • ACTIVE BIOTECH (S)11.95 SEK29.2%

FLOP

  • MOLOGEN (D)1.80 EUR-37.9%
  • SANTHERA (CH)56.40 CHF-20.6%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1906.5%
  • NICOX (F)11.17 EUR481.8%
  • SAREUM HOLDINGS (UK)0.60 GBP172.7%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016